Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AA34893 fixed-dose regimens versus placebo and venlafaxine in major depressive disorder
2007-007025-51Phase 2Terminated
- Sponsor
- Lundbeck
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LU AA34893 in major depressive disorder (MDD) (5 arms), sponsored by Lundbeck. Primary endpoint: Change from baseline in MADRS total score up to week 8. Started Jun 2008; status: terminated.
02
Drugs
LU AA34893
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2007-007025-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007025-51.